1/49
Looks like no tags are added yet.
treatment goal for chronic vs acute leukemias
chronic: not treating for cure
acute: curative intent
upregulated myeloid proliferation leading to excess mature neutrophil production
chronic myeloid leukemia
oncogenic protein resulting in the pathogenesis of CML
philadelphia chromosome
what makes up the philadelphia chromosome
BCR-ABL fusion gene on chromosomes 9 and 22
medical emergency presentation of CML
leukocytosis, WBCs as high as 1,000,000 cells
other presentations of CML
fatigue, sweating, bone pain, weight loss, splenomegaly
diagnosis of CML
bone marrow biopsy and CBC
what is monitored during CML treatment
PCR- polymerase chain reaction
phases of CML
Chronic phase, accelerated phase, and blast crisis
CML phase with progressive myeloid maturation, 10-19% blasts
accelerated phase
terminal phase of CML that clinically resembles acute leukemia
blast crisis
goal of CML treatment
eradicate leukemic clone with minimal toxicity
main drug class used in CML
tyrosine kinase inhibitors (TKIs)
molecular response goal of CML
major (MMR): BCR-ABL <0.1%
ideal molecular response for CML
deep: BCR-ABL <0.01%
first generation TKI
imatinib
how does neutropenia caused by imatinib progress after several years
high during years 1-2 then greatly decreases
2nd generation TKIs
Dasatinib
Nilotinib
Bosutinib
3rd generation TKIs
Ponatinib
4th generation TKIs
asciminib
which TKI must be taken BID
nilotinib
main SE of imatinib
nausea
main SE of dasatinib
fluid retention (pleural effusion)
SEs of nilotinib
QTc interval prolongation
metabolic syndrome
SE's: ponatinib (most toxic agent)
ischemic reactions
vascular occlusion
HTN
SEs of asciminib
musculoskeletal pain
dyslipidemia
signs of relapse from CML
any sign of loss of CCyR or an increase in BCR:ABL transcript to >1%
point mutation in CML that leads to resistance to 1st + 2nd generation TKIs
T315I
what can be used to treat CML with T315I mutation
ponatinib, asciminib, omacetaxine
how to treat accelerated phase CML
higher dose of TKI or new TKI to return to chronic phase
how to treat blast phase CML
treat like acute leukemia + TKI
leukemia with mature B lymphocyte accumulation that do not function properly
chronic lymphoid leukemia (CLL)
main patient demographic for CLL
old white men
presentation of CLL
recurrent infections, lymphadenopathy, hepatosplenomegaly, anemia, thrombocytopenia
how to diagnose CLL and what is the diagnostic criteria
diagnosed off of peripheral blood, monoclonal B lymphocytes >5x10^9/L in peripheral blood
what FISH variables lead to an unfavorable risk in CLL
Del(17p) and Del(11q)
what DNA sequencing variables lead to an unfavorable risk in CLL
TP53 mutated and IGHV <2% mutation
who is treated in CLL
stage III/IV, symptomatic, organ dysfunction
first line treatment option for CLL
BTK inhibitors alone or with chemoimmunotherapy
BTK inhibitor based regimens for CLL
acalabrutinib (continuous) + obinutuzumab OR
zanubrutinib (continuous)
BCL2 inhibitor containing regimens for CLL and duration
venetoclax/ acalabrutinib OR
venetoclax + obinutuzumab
finite duration (1 year)
difference in CLL treatment if pt has del(17p)/TP53 mutation
venetoclax/acalabrutinib + obinutuzumab
clinically significant ADE difference between zanubrutinib and ibrutinib
ibrutinib has higher afib risk
take home message of zanubrutinib vs ibrutinib
zanubrutinib has better response with less toxicity
very significant risk of venetoclax
TLS due to apoptosis of cancer cells
pro-apoptotic proteins released by venetoclax
BIM and PUMA
what interactions are significant with venetoclax use
CYP3A4 and Pgp
how to treat relapse or refractory CLL
switch to alternative regimen
CAR-T after BTK inhibitors and BCL2 inhibitor therapy used
toxicities of acalabrutinib + zanubrutinib
HTN, increased risk of hemorrhage, afib
what peaks early in treatment course with BTK inhibitors but does not signify disease progression
lymphocytosis or tumor flare